Griffin T W, Lister T A, Rybak M E, Rosenthal D S, Canellos G P, Woodruff R, Oliver K T
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1853-6.
Neocarzinostatin (NCS) is a polypeptide antibiotic which has been shown to have antileukemic activity in Japanese trials. Twenty-two patients, who were in relapse with acute nonlymphocytic leukemia refractory to other agents, were studied with two dose schedules of NCS. Schedule 1, 2000-8000 units/m2/day by continuous infusion for 5-10 days, was given to 12 patients and schedule 2, 2000-6000 units/m2/day by iv bolus every 8 hours, was given to ten patients. Clearing of peripheral blast cell was seen in nine of 12 patients treated with schedule 1 and in four of ten patients treated with schedule 2. Bone marrow effect was variable and appeared to be dose-related. No unequivocal complete remissions were seen with either schedule. NCS perturbations of cycling bone marrow cells were studied in two patients receiving the drug by continuous infusion. Both of these patients showed G2 accumulation of marrow cells following treatment. Immunochemically detectable levels of drug were seen in three patients treated with continuous infusion. In summary, NCS has antileukemic effect in patients with acute nonlymphocytic leukemia refractory to other agents. However, its role in the therapy for acute leukemia required further evaluation.
新制癌菌素（NCS）是一种多肽抗生素，在日本的试验中已显示出具有抗白血病活性。对22例急性非淋巴细胞白血病复发且对其他药物耐药的患者，采用两种NCS给药方案进行了研究。方案1为12例患者采用持续输注，剂量为2000 - 8000单位/平方米/天，持续5 - 10天；方案2为10例患者每8小时静脉推注一次，剂量为2000 - 6000单位/平方米/天。采用方案1治疗的12例患者中有9例外周原始细胞清除，采用方案2治疗的10例患者中有4例外周原始细胞清除。骨髓效应各不相同，且似乎与剂量相关。两种方案均未观察到明确的完全缓解。对两名接受持续输注该药的患者研究了NCS对骨髓循环细胞的影响。这两名患者在治疗后均出现骨髓细胞G2期蓄积。在接受持续输注治疗的3例患者中检测到了免疫化学可检测水平的药物。总之，NCS对其他药物耐药的急性非淋巴细胞白血病患者具有抗白血病作用。然而，其在急性白血病治疗中的作用需要进一步评估。
